CPHARMAX, INC.
CLERMONT, FLORIDA



CPHARMAX, INC., based in Clermont, Florida, started its innovative journey on May 28, 2004. The company focuses on developing cutting-edge dietary supplements and gene therapy solutions, particularly for hepatocellular carcinoma research. Their work with interleukin-2 gene therapy has generated exciting results, such as long-term remission of tumors in mice-a breakthrough presented at the American Cancer Society Annual Meeting back in 1996. One standout product from CPHARMAX's portfolio is Arthro SupReviver, a supplement aimed at improving joint mobility and maintaining healthy joints. If you need more information about their offerings or want to connect with them, CPHARMAX can be reached via mail at Citrus Tower Blvd., Suite B in Lake County, Florida, or by phone through numbers like (866) 406-2244 and (352) 243-6300. Under the leadership of President Hanxian Huang, CPHARMAX maintains a strong commitment to reliable marketing standards, reflected in their status as a DoNotMisleadPetitioner (DOMP). The company remains dynamic, with recent updates like the amendment on September 16, 2009, and an annual report release for March 5, 2024. For more insights into their research and products, visit their website at www.cpharmax.com.

KEY FACTS ABOUT CPHARMAX, INC.

Company name
CPHARMAX, INC.
Status
Active
Filed Number
P04000085230
FEI Number
201248655
Date of Incorporation
May 28, 2004
Age - 23 years
Home State
FL
Company Type
Domestic for Profit

CONTACTS

Website
https://cpharmax.com
Phones
(866) 408-2244
(352) 243-6300
(980) 987-1996
(589) 594-1996
(613) 619-1993
(349) 350-1993
(462) 466-1989

CPHARMAX, INC. NEAR ME

Principal Address
3190 CITRUS TOWER BLVD,
SUITE B,
CLERMONT,
FL,
34711,
US

See Also

Officers and Directors

The CPHARMAX, INC. managed by the one person from CLERMONT on following positions: President

Hanxian Huang

Position
President Active
From
CLERMONT, FL





Registered Agent is Hanxian Dr. Huang

From
CLERMONT, 34711

Events

September 16, 2009
AMENDMENT
February 21, 2007
AMENDMENT

Annual Reports

2025
March 22, 2025
2024
March 5, 2024